Exercise in Prematurely Born Preadolescents to Mitigate Cardiovascular Risk and Improve Cognitive Impairment
Launched by HENNER HANSSEN · Jul 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The EXCELSIOR trial is a study looking at how physical exercise can help improve heart health and brain function in children who were born prematurely (before 32 weeks of pregnancy). In this trial, children aged 6 to 12 years will be randomly placed into two groups: one group will participate in a fun exercise program designed for kids, while the other group will receive general advice on healthy habits and exercise. This study is important because it aims to understand if exercise can make a positive difference in the lives of children who may face health challenges due to their early birth.
To be part of this study, children must be born prematurely and be between 6 and 12 years old. However, children who have certain conditions, like attention disorders requiring special education, serious eye problems, or significant disabilities that prevent them from exercising, won't be eligible. If you decide to participate, you can expect to engage in enjoyable activities that promote physical fitness, all while helping researchers learn how exercise can benefit kids born prematurely. This could be a great opportunity to support your child's health and contribute to important research!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Boys and girls born prematurely (\<= 32th week of gestation)
- • aged 6 to 12 years
- • informed consent provided
- Exclusion Criteria:
- • attendance of special education services related to attention disorders
- • colour blindness or any chronic eye disorder
- • being under pharmacological treatment for any mental disorder
- • injuries, significant motor- or other disabilities which prohibit the participation in physical exercise
- • visually provoked epilepsy
- • children for whom no informed consent is provided
About Henner Hanssen
Henner Hanssen is a leading clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a commitment to improving patient outcomes, the organization specializes in designing and conducting clinical trials across various therapeutic areas. Henner Hanssen collaborates with healthcare professionals, regulatory bodies, and industry partners to ensure compliance with the highest ethical standards and scientific integrity. Their focus on patient-centric approaches and data-driven methodologies positions them as a trusted partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Basel Stadt, Switzerland
Patients applied
Trial Officials
Holger Burchert, PhD
Principal Investigator
University of Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported